{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:01:42Z","timestamp":1785441702559,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.transci.2026.104478","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:50:15Z","timestamp":1782575415000},"page":"104478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment of pure red cell aplasia with Orelabrutinib following major ABO-incompatible hematopoietic stem cell transplantation for acute myeloid leukemia: A case report"],"prefix":"10.1016","volume":"65","author":[{"given":"Siqi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tierong","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxiang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.transci.2026.104478_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.transci.2026.104478_bib2","unstructured":"International Society of Blood Transfusion. Red cell immunogenetics and blood group terminology. https:\/\/www.isbtweb.org\/working-parties\/red-cell-immunogenetics-and-blood-group-terminology; 2021 [accessed 1 October 2021]."},{"issue":"3","key":"10.1016\/j.transci.2026.104478_bib3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/trf.17743","article-title":"Successful treatment pure red cell aplasia after ABO major mismatched allogeneic hematopoietic stem cell transplantation with avatrombopag and low dose rituximab","volume":"64","author":"Cao","year":"2024","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.transci.2026.104478_bib4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41409-020-01124-6","article-title":"Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question","volume":"56","author":"Marco-Ayala","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.transci.2026.104478_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/tme.12121","article-title":"Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation","volume":"24","author":"Khan","year":"2014","journal-title":"Transfus Med"},{"issue":"21","key":"10.1016\/j.transci.2026.104478_bib6","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1182\/bloodadvances.2023010587","article-title":"Treatment strategy for acquired pure red cell aplasia: a systematic review and meta-analysis","volume":"7","author":"Lobbes","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2026.104478_bib7","article-title":"Cord blood therapy for pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: case series and review","volume":"15","author":"Li","year":"2025","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.transci.2026.104478_bib8","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41409-022-01590-0","article-title":"Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib","volume":"57","author":"Arslan","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"27","key":"10.1016\/j.transci.2026.104478_bib9","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033880","article-title":"Orelabrutinib versus ibrutinib for patients with refractory\/relapsed primary central nervous system lymphoma: an efficacy and safety analysis","volume":"102","author":"Qiao","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"16","key":"10.1016\/j.transci.2026.104478_bib10","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1182\/bloodadvances.2022009168","article-title":"Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1\/2, open-label, multicenter, single-arm study","volume":"7","author":"Deng","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2026.104478_bib11","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/13543784.2022.2113055","article-title":"Pure red cell aplasia after hematopoietic stem cell transplantation - experimental therapeutic approaches","volume":"31","author":"Vo","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.transci.2026.104478_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000441507","article-title":"ABO-mismatched allogeneic hematopoietic stem cell transplantation","volume":"43","author":"Worel","year":"2016","journal-title":"Transfus Med Hemother"},{"issue":"4","key":"10.1016\/j.transci.2026.104478_bib13","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.17463","article-title":"Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study","volume":"193","author":"Longval","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2026.104478_bib14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1537-2995.2011.03295.x","article-title":"Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange","volume":"52","author":"Curley","year":"2012","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.transci.2026.104478_bib15","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.bbmt.2013.04.004","article-title":"Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors","volume":"19","author":"Hirokawa","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.transci.2026.104478_bib16","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/bmt.2009.202","article-title":"Self-limited hemolysis due to anti-D passenger lymphocyte syndrome in allogeneic hematopoietic stem cell transplantation","volume":"45","author":"Adams","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.transci.2026.104478_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14915","article-title":"Optimal dose of rituximab in ABO-incompatible kidney transplantation in patients with low anti-A\/B antibody titers: a single-center retrospective cohort study","volume":"37","author":"Okada","year":"2023","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transci.2026.104478_bib18","doi-asserted-by":"crossref","first-page":"1504495","DOI":"10.3389\/fimmu.2024.1504495","article-title":"Outcomes of ABO-incompatible kidney transplants with very high isoagglutinin titers: a single-center experience and literature review","volume":"15","author":"Naciri Bennani","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.transci.2026.104478_bib19","doi-asserted-by":"crossref","first-page":"585628","DOI":"10.3389\/fmed.2020.585628","article-title":"Antigen-specific immunoadsorption with the glycosorb\u00ae ABO immunoadsorption system as a novel treatment modality in pure red cell aplasia following major and bidirectional abo-incompatible allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Handisurya","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.transci.2026.104478_bib20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.14740\/jh1195","article-title":"Refractory pure red blood cell aplasia secondary to major ABO-incompatible allogeneic stem cell transplantation successfully treated with daratumumab","volume":"12","author":"Wu","year":"2023","journal-title":"J Hematol"},{"issue":"2","key":"10.1016\/j.transci.2026.104478_bib21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41409-021-01507-3","article-title":"Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation","volume":"57","author":"Martino","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.transci.2026.104478_bib22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-025-01315-8","article-title":"Daratumumab for PRCA after HCT: study and practical considerations from the EBMT transplant complications working party","volume":"15","author":"Gagelmann","year":"2025","journal-title":"Blood Cancer J"},{"issue":"Suppl 1","key":"10.1016\/j.transci.2026.104478_bib23","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2025-2443","article-title":"Ibrutinib in the treatment of allogeneic stem cell transplant-related pure red cell aplasia: A single center experience","volume":"146","author":"Azbell","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.transci.2026.104478_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241282570","article-title":"Relapsed\/refractory pure red cell aplasia in chronic lymphocytic leukemia successfully treated with acalabrutinib: a case report and review of the literature","volume":"15","author":"Fresa","year":"2024","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"10.1016\/j.transci.2026.104478_bib25","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/bjh.19146","article-title":"A pilot study of orelabrutinib treatment in three cases of refractory\/relapsed autoimmune haemolytic anaemia\/Evans syndrome","volume":"204","author":"Liu","year":"2024","journal-title":"Br J Haematol"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050226001102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050226001102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:30:01Z","timestamp":1785439801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050226001102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1473050226001102"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2026.104478","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful treatment of pure red cell aplasia with Orelabrutinib following major ABO-incompatible hematopoietic stem cell transplantation for acute myeloid leukemia: A case report","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2026.104478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104478"}}